Enroll Now or Learn More
OVERVIEW
LEARN MORE
MODULES
Module A - Creating Value
Module B - Managing Value
Module C - Growing Value
DATES
Module A: October 7-8, 2009 (2 days)
Module B: November 2-3, 2009 (2 days)
Module C: December 8-9, 2009 (2 days)
Additional dates:
Module A: October 7-8, 2010
Module B: November 4-5, 2010
Module C: December 7-8, 2010
FEES
Individuals: $1950 USD per module
Full Program (all 3 modules): $5500 USD (savings of $350 USD)
Corporate offer: 3 Full Program registrations for $15,000 USD
Scholarship Application
SPEAKERS
NETWORKING RECEPTION
SPONSORS
PAST ATTENDEES
LOGISTICS
BROCHURE
PODCAST
RELATED VIDEO
TESTIMONIALS
Note: All speakers and fees are subject to change.

Speakers
Bio Exec Institute

Martin Babler
President & CEO, Talima Therapeutics, Inc.

Martin Babler was until recently VP of Immunology Sales and Marketing at Genentech with responsibility for Xolair, Rituxan Immunology and the late stage Immunology pipeline.

Prior to this, Martin was Senior Director and head of Commercial Development in charge of marketing and strategic input for all products in Genentech's pipeline across the different therapeutic areas. His team was focused on creating high value assets in close collaboration with Research and Development and introduced several new tools and systems to the organization that help optimize product launches.

Martin joined Genentech several years ago as Director of Marketing in the Cardiovascular Franchise.

Prior to joining Genentech, Martin held various roles of increasing responsibility in sales, sales management, marketing and business development on a global as well as affiliate level with Eli Lilly and Company.

Martin Babler holds a degree in Pharmacy/Pharmacology from the ETH in Zurich, Switzerland and has attended the Executive Development Program at Kellogg Graduate School of Management.

[top of page]


Ashraf Hanna, M.D., Ph.D.
Vice President, Alliance Management and Portfolio Planning, Genentech, Inc.

Ashraf Hanna, 38, will join Genentech in a newly created position as vice president, Alliance Management and Portfolio Planning, reporting to Susan Desmond-Hellmann, M.D., M.P.H., president, Product Development. Working with Business Development, the Project Portfolio Management Group, and Research and Development, Hanna will be responsible for establishing, implementing and evaluating alliance management strategy and process.

Prior to joining Genentech, Hanna was vice president at Tanox, with responsibilities for strategic planning and business development. Prior to that, Hanna worked for McKinsey and Company and was a medical resident at Metrowest Medical Center.

Hanna holds a Bachelor of Arts degree in Physics from the University of Chicago, a doctorate in Physics from Harvard University and a medical degree from the University of Massachusetts Medical School.

[top of page]


Abhay Joshi, Ph.D.
President & CEO, Alvine Pharmaceuticals

Dr. Abhay Joshi is the President, CEO and Director of Alvine Pharmaceuticals, Inc. He has over eighteen years of global operations and research and development experience in biologic, pharmaceutical and medical device industries in the United States, Europe, Latin America and Asia Pacific. Prior to Alvine, Dr. Joshi served as an Executive Vice President, Chief Technical Officer and member of Executive Committee at CoTherix, Inc., now Actelion Ltd. Dr Joshi held various senior management positions at Allergan. He was the Vice President of Global Technical Operations, Specialty Pharmaceuticals at Allergan where he was responsible for the company's global biologics manufacturing operations for BOTOX® and its Latin America and Asia Pacific pharmaceutical operations.

Dr. Joshi received his BTech in Chemical Engineering from the Indian Institute of Technology, New Delhi, an MSE and a Ph.D. in Chemical Engineering from the University of Michigan, Ann Arbor, and an MBA from the University of California, Irvine. Dr. Joshi holds an adjunct faculty appointment at the University of Southern California School of Pharmaceutical Sciences. 

[top of page]


Eric J. Patzer, Ph.D.
President and CEO, Aridis Pharmaceuticals, LLC

Dr. Patzer has 22 years experience in product development beginning his career at Genentech in 1981. Dr. Patzer played a key role in the development of Activase®, Protropin®, Herceptin® and Xolair®. As Vice President, Product Development, Dr. Patzer's responsibilities included analytical development, hybridoma development, preclinical animal testing, QA/QC and project and portfolio management. Dr. Patzer played a key role in developing the product development and management process at Genentech.

In 1996 Dr. Patzer joined Aviron (now MedImmune Vaccines) as Vice President, Development. Under his leadership, the Development organization was expanded to support the development of the intranasal influenza vaccine (FluMist®) through preclinical and clinical development and resulting in U.S. regulatory approval (FDA). The organization consisted of the following departments: analytical development, clinical QC testing, process and formulation development, clinical manufacturing, clinical laboratory testing and project management. Dr. Patzer was the project team leader of the intranasal influenza vaccine, FluMist®, during preclinical and clinical development.

In 2003, Dr. Patzer founded Aridis Pharmaceuticals, LLC to develop convenient and cost effective therapeutics for infectious diseases focused on live attenuated vaccines and antibody therapies that can be delivered in simple oral or pulmonary dosage forms and that can be stored outside the cold chain (i.e., are stable at room temperature and above). Aridis is currently developing two temperature stable oral vaccines against rotavirus gastroenteritis in infants and shigellosis in adults and children and a temperature stable antibody therapeutic against pulmonary infections with Pseudomonas aeruginosa.

[top of page]


Janet L. "Lucy" Rose
Managing Director, Life Sciences Regulatory & Capital Markets Consulting, Deloitte & Touche LLP
Former Director of the Office of Training and Communications and DDMAC, CDER, FDA

Lucy Rose is uniquely qualified to provide regulatory training and consulting to the pharmaceutical industry and its service support providers, such as public relations firms, advertising agencies and CME providers. Her combination of education and experience, coupled with her extensive experience as a trainer and educator, provides the depth of knowledge and expertise necessary to equip companies to face a promotional environment changing at warp speed.

From 1995-97, Lucy served as the Director of Office of Training and Communications for the Center for Drug Evaluation and Research (CDER) of the Food and Drug Administration. There she designed and implemented programs to improve external communications with consumers, patients, the pharmaceutical industry and health care professionals. Additionally, she designed and implemented programs to improve employee performance, including leadership and management development. Examples of programs introduced during Lucy?s leadership include: design and implementation of CDER's World Wide Web Site, Live Satellite Educational TV programs with the pharmaceutical industry, comprehensive introductory training programs for new reviewers, and design and implementation of CDER's crisis communication program.

Lucy led CDER's Division of Drug Marketing, Advertising and Communications (DDMAC) from 1993 to 1995. In this capacity, she was responsible for the regulatory oversight of all prescription drug advertising and marketing to U.S. health care professionals and consumers. Under Lucy?s leadership, the division intiated a philosophy of transparency and educational outreach, in addition to setting clear review priorities and timeliness goals for industry-requested comments, such as voluntary submissions of launch campaigns. Special challenges encountered during her tenure included the FDA Industry Supported Scientific and Education Guidance and the evolution of Direct-to-Consumer Broadcast advertising, among others.

Prior to joining FDA, Lucy was associated for seven years with Mead Johnson Pharmaceuticals, a division of Bristol-Myers Squibb Pharmaceuticals. She began her career as a sales representative, served as a regional sales trainer, and for four years was the District Sales Manager in Washington, DC. Lucy earned a B.S. degree in biology from Salem College in Winston-Salem, NC and an M.B.A. from Averett College. In addition, Lucy practiced as a board-certified Physician Assistant, having graduated from the Wake Forest School of Medicine.

Lucy has been honored with a number of awards. The FDA twice selected her for their highest leadership accolade, the Award of Merit, for her work at DDMAC and at Office of Training and Communication. In 2004, Phame, an award organiation that evaluates Direct-to-Consumer promotion, elected her to its DTC Hall of Fame for her many years of leadership in the DTC arena. Additionally, Lucy speaks extensively at professional conferences on the regulatory and compliance issues surrounding the promotion of prescription drugs. She is an active member of the Drug Information Association and the Food and Drug Law Institute.

[top of page]


David Summa
Chief Business Advisor, Acumen Pharmaceuticals, Inc.

David Summa is currently the Chief Business Advisor of Acumen Pharmaceuticals, a pre-clinical drug development company that is developing the first effective therapeutics and diagnostics that prevent Alzheimer's disease.

Prior to joining Acumen, Dave was the President and CEO of Mendel Biotechnology, a successful genomics company that was the first to functionally characterize all the transcription factors in arabidopsis thaliana. Mendel's traits now form the core of the Monsanto product pipeline. Before joining the ranks of Bay Area biotech entrepreneurs, Dave was a Vice President at Monsanto where he created Renessen, the joint venture between Cargill and Monsanto. Prior to joining Monsanto, Dave was a partner at McKinsey & Company, Inc. where he was the global leader of the Innovation Practice.

Dave received his BS and MS from MIT in the department of Chemical Engineering.

[top of page]


Key Industry Speakers

Day 1

Day 2

Day 3

Day 4

Day 5

Day 6

 

[top of page]